Department of Surgery, Yokohama City University, Yokohama, Japan.
Department of Surgery, Yokohama City University, Yokohama, Japan;
In Vivo. 2024 Mar-Apr;38(2):904-910. doi: 10.21873/invivo.13517.
BACKGROUND/AIM: The albumin-globulin ratio (AGR) is a useful biomarker for predicting postoperative complications and a poor prognosis in patients with various types of cancer and can be evaluated without invasive testing or surgery. In this study, we aimed to evaluate the usefulness of the AGR in predicting the short- and long-term prognoses of patients with gastric cancer who underwent radical resection at our institution.
This study is a retrospective cohort analysis in which eligible patients were selected from the medical records of patients who underwent radical resection for gastric cancer at Yokohama City University from 2000 to 2020 and their medical records were reviewed. A total of 240 patients with gastric cancer were classified into high-AGR (>1.57) and low-AGR (≤1.57) groups and their overall survival (OS), recurrence-free survival (RFS), and postoperative complication rates were compared.
Of the total 240 patients, 87 were classified into the high AGR group and 153 were classified into the low AGR group; the incidence of postoperative complications in the two groups did not differ to a statistically significant extent (34.4% vs. 39.2%, p=0.491). The long-term findings showed that the 5-year OS and RFS rates were significantly better in the high AGR group [84.0% vs. 64.8% (p=0.005), 80.0% vs. 61.9% (p=0.015), respectively].
Preoperative low AGR is a risk factor for OS and DFS in patients with gastric cancer who undergo surgery. The AGR may be a useful biomarker that can be applied as a prognostic indicator for patients with gastric cancer.
背景/目的：白蛋白-球蛋白比值（AGR）是一种有用的生物标志物，可预测各种类型癌症患者术后并发症和不良预后，且无需进行侵入性检查或手术即可评估。本研究旨在评估 AGR 在预测我院接受根治性切除术的胃癌患者短期和长期预后中的作用。
这是一项回顾性队列分析研究，我们从 2000 年至 2020 年在横滨市立大学接受胃癌根治性切除术的患者病历中选择符合条件的患者，并对其病历进行了回顾。共有 240 例胃癌患者被分为高 AGR（>1.57）和低 AGR（≤1.57）组，并比较了他们的总生存期（OS）、无复发生存期（RFS）和术后并发症发生率。
在 240 例患者中，87 例被归入高 AGR 组，153 例被归入低 AGR 组；两组术后并发症发生率无统计学差异（34.4% vs. 39.2%，p=0.491）。长期随访结果显示，高 AGR 组患者的 5 年 OS 和 RFS 率显著更好[84.0% vs. 64.8%（p=0.005），80.0% vs. 61.9%（p=0.015）]。
术前低 AGR 是接受手术治疗的胃癌患者 OS 和 DFS 的危险因素。AGR 可能是一种有用的生物标志物，可作为胃癌患者的预后指标。
